Roche to present new drug data at ECC 2013

Roche has announced plans to attend the 2013 European Cancer Congress (ECC) at the end of the month, where it will share data on its latest oncology innovations.

During the event in Amsterdam from September 27th to October 1st, the company's medicines will be featured in more than 138 scientific presentations, with findings to focus on 18 drugs directed against a broad range of therapeutic targets.

New clinical trial data will further reinforce the safety and efficacy profiles of the established therapies Avastin, Herceptin, Kadcyla and Zelboraf, while promising results for the investigational products MPDL3280A, cobimetinib and alectinib will also be shared.

Dr Hal Barron, chief medical officer and head of global product development at Roche, said: "This data reflects our commitment to develop new targeted anti-cancer medicines as well as to explore how our approved medicines, such as Zelboraf, Avastin and Herceptin, can benefit more patients."

This comes in the same month that the company received a recommendation for EU approval of Kadclya as a therapy for breast cancer from the European Medicines Agency's Committee for Medicinal Products for Human Use.